NCM
ANEB

Nantahala Capital Management’s Anebulo Pharmaceuticals ANEB Stock Holding History

Nantahala Capital Management’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,036,325
Closed -$3.07M – 153
2025
Q4 		$3.07M Hold
3,036,325
– – 0.1% 121
2025
Q3 		$7.59M Hold
3,036,325
– – 0.26% 86
2025
Q2 		$4.37M Hold
3,036,325
– – 0.17% 97
2025
Q1 		$3.95M Hold
3,036,325
– – 0.16% 81
2024
Q4 		$5.1M Buy
3,036,325
+2,525,252
+494% +$4.16M 0.22% 77
2024
Q3 		$986K Hold
511,073
– – 0.05% 113
2024
Q2 		$1.4M Hold
511,073
– – 0.08% 99
2024
Q1 		$1.47M Hold
511,073
– – 0.08% 92
2023
Q4 		$1.24M Hold
511,073
– – 0.07% 103
2023
Q3 		$1.56M Hold
511,073
– – 0.13% 95
2023
Q2 		$1.2M Hold
511,073
– – 0.12% 88
2023
Q1 		$1.48M Hold
511,073
– – 0.11% 82
2022
Q4 		$1.24M Hold
511,073
– – 0.08% 83
2022
Q3 		$1.43M Buy
+511,073
New +$1.82M 0.09% 83

Nantahala Capital Management's ANEB Position: Q1 2026 in Review

Nantahala Capital Management sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 3,036,325 shares — an estimated $3.07M sold.

Nantahala Capital Management first reported a position in ANEB in Q3 2022 and held it in 14 quarters. The position peaked at $7.59M in Q3 2025. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.

  • Nantahala Capital Management reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nantahala Capital Management sold 3,036,325 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $3.07M.
  • Nantahala Capital Management first reported a position in Anebulo Pharmaceuticals in Q3 2022 and held it in 14 quarters.
  • Nantahala Capital Management's Anebulo Pharmaceuticals position peaked at $7.59M in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.